MedTrace Logo

Extracellular Water in Covid 19 Pneumonia

NCT04416009 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2020-06-04

No results posted yet for this study

Summary

According to various studies Covid 19 pneumonia has a very similar clinical course to Acute Respiratory Distress Syndrome (ARDS) which has clarified by Berlin definition. Based on this similarity, extracellular fluid of lungs and diffuse alveolar damage should be observed in covid 19 pneumonia as well. Extracellular water (ECW) can be determine by using whole body bioimpedence system (NİCaS). The aim of this study is to investigate the effect of ECW on the clinical apperence of covid 19 pneumonia clinical course.

Conditions

  • Extracellular Fluid Alteration
  • Corona Virus Infection

Interventions

DEVICE

NİCaS

whole body bioimpedence method

Sponsors & Collaborators

  • Gaziosmanpasa Research and Education Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-05
Primary Completion
2020-12-20
Completion
2021-02-20
FDA Device
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416009 on ClinicalTrials.gov